Illumina ILMN

  1. All
  2. Commentary
  3. Headlines
    1. Illumina's ( ILMN ) CEO Jay Flatley on Q3 2014 Results - Earnings Call Transcript


      Tue, 21 Oct 2014

      Illumina 's ( ILMN ) CEO Jay Flatley on Q3 2014 Results - Earnings Call Transcript

    2. Illumina ( ILMN ) Q3 2014 Results - Earnings Call Webcast


      Mon, 20 Oct 2014

      Illumina ( ILMN ) Q3 2014 Results - Earnings Call Webcast

    3. Notable earnings after Monday’s close


      Sun, 19 Oct 2014

      AAPL , BRO , BXS , CDNS , CE , CMG , CYS , ELS , EWBC , GLF , HLX , HSTM , HXL , ILMN , KALU , PCH , PKG , RCII , RMBS , STLD , TXN , UCTT , WERN , ZION Post your comment!

    4. Ilumina to report on October 20


      Mon, 6 Oct 2014

      Ilumina (NASDAQ: ILMN ) will report Q3 results on October 20 after the close. The conference call will begin at 2:00 pm PT. Consensus view is EPS of $0.56 on revenues of $451M. Post your comment!

    5. BRIEF-Hybrigenics subsidiary Helixio buys an Illumina sequencer


      Wed, 1 Oct 2014

      * Subsidiary Helixio buys an Illumina sequencer Further company coverage: (Gdynia Newsroom: +48 58 698 39 20)

    6. A Shift in Health-Care M&A Activity


      Sat, 23 Aug 2014

      eventually, we believe it could be a long-term positive for ICON by driving greater outsourcing. Waterhouse : I think Illumina ILMN is an interesting company. We think llumina is currently monopolizing the genome sequencing space. This industry

    7. Illumina ’s Growth and Margin Expansion Momentum Remain Impressive


      Thu, 24 Jul 2014

      Illumina posted impressive second-quarter results that ..... estimate. We think plenty of tailwinds remain for Illumina over the coming years as the genome sequencing market continues to expand, Illumina takes market share, and upcoming regulatory

    8. Qiagen Still Faces Pressure From U.S. HPV Market, Expects More Sequencing Delays


      Thu, 8 May 2014

      the market in mid- to late 2015, considerably behind our own estimate and management's previous expectations. We think Illumina 's recent advances in the sequencing market combined with Qiagen's further delays will make it harder for the company to

    9. Illumina shares up on higher sales of gene-sequencing products


      Tue, 22 Apr 2014

      (Reuters) - Life-science tool maker Illumina Inc reported a better-than-expected jump in quarterly revenue, helped by strong sales of its gene-sequencing products.

    10. New Product Launches Should Support Illumina ’s Strong Growth Trajectory


      Wed, 29 Jan 2014

      Illumina ’s fourth-quarter results came in mostly ..... investor day. As we previously stated, Illumina ’s current growth has exceeded our expectations ..... projections. We also plan to further reevaluate Illumina ’s longer-term opportunity in the genome

    « Prev12345Next »
    Content Partners